Bioxyne forecasts doubling of revenue amid ‘$100m gummy opportunity’ by Steve Jones September 26, 2024September 26, 2024 Bioxyne has forecast revenues will double to A$20 million in FY25 on the back of contracts […]
Montu named as customer behind ‘$28m’ gummy deal as Bioxyne resumes trading on ASX by Steve Jones September 18, 2024September 19, 2024
Financial results: Rua Bioscience; Elixinol Wellness; Argent Biopharma; Wellnex Life; InhaleRx; Bioxyne by Martin Lane and Steve Jones September 2, 2024September 3, 2024
Company news: Rua Bioscience; Avecho; Bioxyne/BLS; iX Biopharma; Ecofibre; Zelira by Steve Jones and Martin Lane August 28, 2024January 13, 2025
Company news: Avecho; Bioxyne; Elixinol Wellness; IDT Australia; Melodiol Global Health; Zelira by Steve Jones July 31, 2024November 25, 2024
Company news: Ecofibre; Bioxyne/BLS; Aurora Cannabis by Steve Jones and Martin Lane May 14, 2024July 16, 2024
Financial results: Bioxyne; Melodiol Global Health; Emyria; Zelira; Elixinol; Wellnex Life; Argent BioPharma by Steve Jones May 1, 2024May 1, 2024
Company news: Bioxyne/BLS; Rua Bioscience; Botanix; Melodiol Global Health; Zelira; Argent BioPharma by Martin Lane and Steve Jones April 16, 2024July 16, 2024
Financial results: Bioxyne; Rua Bioscience; Bod Science; Avecho; Wellnex Life; MGC Pharma; Cannasouth by Steve Jones March 7, 2024March 7, 2024
Company news: Bioxyne/BLS; Wellnex Life; Elixinol Wellness; Althea; Health House; Rua Bioscience by Steve Jones and Martin Lane February 7, 2024November 25, 2024
